Nicolas Acquavella Pesantes, M.D.
- Office: 305-243-6608
- Fax: 305-243-3168
- Internal Medicine
- Hematology/Oncology - Internal Medicine
- American Board of Internal Med-Medical Oncology
- American Board of Internal Medicine
- Assistant Professor of Clinical Medicine
- Member, Immunotherapy Program
- Member, Melanoma Program
- Member, Phase I Clinical Trials Program
1. A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAF V600 Mutant Melanoma.
5. A phase 1b study of intratumoral CAVATAK (Coxsackievirus A21) and ipilimumab in patients with advanced melanoma.
6. Proof of concept study of vorinostat, a histone deacetylase inhibitor, in patients with class 2 high risk uveal melanoma.
7. A phase 1 Open-label, Multi-center study of the Safety and Efficacy of IMCgp100 using the Intrapatient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma (Opening soon)
MD, Universidad Central de Venezuela
Residency, Yale New Haven Hospitals
Fellowship, National Cancer Institute / National Institutes of Health
Nicolas Acquavella, M.D., is a board-certified medical oncologist dedicated to providing innovative and advanced treatment options to patients with metastatic melanoma and pancreatic cancer. Dr. Acquavella’s research focuses on mobilizing the body’s immune system to seek out and destroy cancer cells. In close collaboration with a multidisciplinary group of scientists, pharmaceutical companies and clinicians Dr. Acquavella works to move the most promising cancer therapies from the laboratory into the clinic. In collaboration with his colleagues at the Bascom Palmer Eye Institute at the University of Miami – the No. 1 eye hospital in the nation – Dr. Acquavella is committed to develop novel therapies for uveal melanoma, a rare type of melanoma that occurs in the eye and for which no effective therapies exist. His current research involves combining immune-based therapies with viruses genetically modified to destroy cancer cells.